EN
登录

AmyriAD Therapeutics从 ADvantage收购 AD04阿尔茨海默病项目,进一步拓展其临床阶段认知障碍治疗管线

AmyriAD Therapeutics Acquires AD04 Alzheimer's Program from ADvantage, Further Expanding Its Clinical-Stage Cognition Pipeline

CISION 等信源发布 2026-11-16 21:42

可切换为仅中文


Phase 2b-ready program targeting neuroinflammation in mild Alzheimer's disease complements lead program Ismidenon in moderate Alzheimer's

针对轻度阿尔茨海默病神经炎症的2b期临床就绪项目,与主打项目Ismidenon(用于中度阿尔茨海默病)形成互补

AMSTERDAM

阿姆斯特丹

,

,

Nov. 16, 2026

2026年11月16日

/PRNewswire/ -- AmyriAD Therapeutics B.V. ('AmyriAD'), a clinical-stage biopharmaceutical company developing therapies that address biological drivers of cognitive decline, today announced the acquisition of the AD04 Alzheimer's disease program and related assets from ADvantage Therapeutics, Inc. ('ADvantage').

/美通社/ -- 临床阶段生物制药公司AmyriAD Therapeutics B.V.(“AmyriAD”)致力于开发针对认知衰退生物学驱动因素的治疗方案,今日宣布从ADvantage Therapeutics, Inc.(“ADvantage”)收购AD04阿尔茨海默病项目及相关资产。

The acquisition adds a Phase 2b-ready program targeting neuroinflammation in mild Alzheimer's disease, complementing AmyriAD's lead program, Ismidenon, in moderate Alzheimer's..

此次收购增加了一项针对轻度阿尔茨海默病神经炎症的、已具备开展2b期临床试验条件的项目,与AmyriAD针对中度阿尔茨海默病的领先项目Ismidenon形成互补。

AD04 is an investigational drug subcutaneously administered. Its mechanism of action is initiated by peripheral inflammation and results in inflammation resolution in the brain and the elimination of waste, including lipid microdroplets.

AD04是一种皮下注射的在研药物。其作用机制由外周炎症启动,进而促使脑部炎症消退并清除包括脂质微滴在内的废物。

Strategic Rationale

战略依据

'Cognitive decline threatens people's independence, relationships and daily lives. Addressing it requires more treatment options across different biological mechanisms and stages of disease,' said K. Ranga Rama Krishnan, Chairman of the Board and CEO of AmyriAD. 'Following our acquisition of Recognify Life Sciences, AD04 further expands our cognition pipeline alongside lead program Ismidenon.

“认知能力下降威胁着人们的独立性、人际关系和日常生活。应对这一问题需要在不同的生物机制和疾病阶段提供更多治疗选择,”AmyriAD 公司董事会主席兼首席执行官 K. Ranga Rama Krishnan 表示。“在收购 Recognify Life Sciences 之后,AD04 与我们的领先项目 Ismidenon 一起,进一步丰富了我们的认知领域产品管线。”

We are building this portfolio with a clear purpose: helping people preserve the abilities that make life their own.'.

我们构建这一产品组合有着明确的目标:帮助人们保留那些让生活独具特色的能力。

'AD04's clinical findings provide a compelling foundation for its continued development in mild Alzheimer's disease,' said Jeffrey B. Madden, Chief Executive Officer of ADvantage Therapeutics. 'I'm excited to combine our experience with AD04 and AmyriAD's expertise in cognition as we advance toward Phase 2b, building on the program's Innovation Passport under the United Kingdom's Innovative Licensing and Access Pathway (ILAP).'.

“AD04的临床发现为其在轻度阿尔茨海默病领域的持续开发提供了令人信服的依据,”ADvantage Therapeutics首席执行官Jeffrey B. Madden表示。“随着我们向IIb期临床试验推进,并在英国创新许可和准入途径(ILAP)下‘创新护照’计划的基础上继续开展工作,我感到振奋的是,我们将把我们在AD04项目上的经验与AmyriAD在认知领域的专业知识相结合。”

AD04's clinical rationale emerged from AFF006, a 332-patient Phase 2 Alzheimer's vaccine study. In this study, AD04 served as a control treatment. AD04 is based on a proprietary formulation of aluminum hydroxide hydrogel with a specific dosage. Exploratory post hoc analyses of patients who received AD04 identified signals of slower cognitive decline and reduced hippocampal volume loss..

AD04的临床理论基础源于AFF006研究,这是一项纳入332名患者的阿尔茨海默病疫苗II期临床试验。在该研究中,AD04作为对照治疗。AD04基于一种具有特定剂量的专有氢氧化铝水凝胶制剂。对接受AD04治疗的患者进行的探索性事后分析发现,其认知衰退速度较慢且海马体积丢失减少的信号。

Development Plan

发展计划

AmyriAD intends to advance AD04 into Phase 2b development in mild Alzheimer's disease to prospectively evaluate its safety and efficacy. The program has received an Innovation Passport under the United Kingdom's Innovative Licensing and Access Pathway.

AmyriAD 计划推进 AD04 进入针对轻度阿尔茨海默病的 IIb 期临床开发,以前瞻性评估其安全性和有效性。该项目已获得英国创新许可和准入途径(ILAP)下的“创新护照”资格。

Transaction Details

交易详情

Under the terms of the agreement, AmyriAD acquired worldwide rights to AD04, including associated intellectual property, clinical data and regulatory assets.

根据协议条款,AmyriAD 获得了 AD04 的全球权利,包括相关的知识产权、临床数据和监管资产。

Jeffrey B. Madden and members of ADvantage's clinical and scientific team will continue to support AD04 in advisory roles, providing continuity and program expertise as AmyriAD advances development.

Jeffrey B. Madden 以及 ADvantage 临床与科学团队的成员将继续以顾问身份为 AD04 提供支持,在 AmyriAD 推进开发的过程中确保连续性和提供项目专业知识。

About AD04

关于 AD04

AD04 is an investigational drug, subcutaneously administered, based on an aluminum hydroxide hydrogel, with a specific and proprietary dosage. Its proposed mechanism targets immune processes relevant to neuroinflammation.

AD04 是一种在研药物,采用基于氢氧化铝水凝胶的专有特定剂量配方,经皮下给药。其作用机制旨在靶向与神经炎症相关的免疫过程。

About Ismidenon (AD-101)

关于伊斯米德农(AD-101)

Ismidenon (AD-101) is AmyriAD's lead investigational program, being developed as an oral add-on symptomatic treatment for cognitive impairment in moderate Alzheimer's disease. It targets presynaptic T-type calcium channels to increase acetylcholine release. Studied in more than 500 patients, Ismidenon is moving to a Phase 2 study..

Ismidenon(AD-101)是AmyriAD公司的主要研究项目,正在开发为一种口服附加对症治疗药物,用于改善中度阿尔茨海默病患者的认知障碍。它靶向突触前T型钙通道,以增加乙酰胆碱的释放。Ismidenon已在500多名患者中进行了研究,目前正进入II期临床试验。

About RL-007 (Inidascamine)

关于 RL-007(伊尼达斯卡明)

RL-007 is an investigational oral small molecule being developed for cognitive impairment. It modulates cholinergic, glutamatergic and gamma-aminobutyric acid type B (GABA-B) receptor signaling and has completed Phase 2a and Phase 2b studies in cognitive impairment associated with schizophrenia. AmyriAD plans extended-release formulation development and a pharmacokinetic study to guide further development..

RL-007 是一种在研的口服小分子药物,正在开发用于治疗认知障碍。它调节胆碱能、谷氨酸能和 γ-氨基丁酸 B 型(GABA-B)受体信号传导,并已完成针对精神分裂症相关认知障碍的 IIa 期和 IIb 期临床研究。AmyriAD 计划开发缓释制剂并开展药代动力学研究,以指导后续开发。

About AmyriAD Therapeutics

关于 AmyriAD 治疗公司

AmyriAD Therapeutics B.V. is a clinical-stage biopharmaceutical company developing therapies targeting biological drivers of cognitive decline. Anchored by lead program Ismidenon (AD-101), AmyriAD is building a portfolio of complementary programs across biological mechanisms and stages of cognitive decline, each with its own clinical development path.

AmyriAD Therapeutics B.V. 是一家处于临床阶段的生物制药公司,致力于开发针对认知衰退生物学驱动因素的治疗方案。以核心项目 Ismidenon(AD-101)为基础,AmyriAD 正在构建一个涵盖不同生物学机制和认知衰退阶段的互补项目组合,每个项目均拥有独立的临床开发路径。

AmyriAD is headquartered in Amsterdam, the Netherlands. Visit .

AmyriAD 总部位于荷兰阿姆斯特丹。访问

www.amyriadtherapeutics.com

www.amyriadtherapeutics.com

.

。

Forward-Looking Statements

前瞻性陈述

This release contains forward-looking statements regarding the acquisition's anticipated benefits and planned clinical development. Actual results may differ materially due to clinical, regulatory, financing and other drug-development risks. Earlier findings may not be replicated. AmyriAD undertakes no obligation to update these statements except as required by law..

本公告包含有关收购预期收益及计划临床开发的前瞻性陈述。由于临床、监管、融资及其他药物开发风险,实际结果可能与前瞻性陈述存在重大差异。早期研究结果未必能够复现。除法律要求外,AmyriAD 不承担更新这些陈述的义务。

Contacts

联系人

Kim Bruin,

金·布鲁因,

[email protected]

[email protected]

(Investors)

(投资者)

Ankil Patel, 917-561-6464,

安基尔·帕特尔,917-561-6464,

[email protected]

[email protected]

(Media)

(媒体)

SOURCE AmyriAD Therapeutics

来源:AmyriAD Therapeutics